Form F-1 Prospectus SEC Filing
Filed with ASX · · 125 pages · English
Alison Newman, Esq. Zev Bomrind, Esq. Fox Rothschild LLP 101 Park Avenue New York, NY 10178 (212) 878-7997 Barry I. Grossman, Esq. Sarah E. Williams, Esq. Ellenoff Grossman & Schole LLP 1345 Avenue of the Americas New York, NY 10105 (212) 370-1300 Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective. If any of t
Genetic Technologies Limited on 6ix
Earlier from Genetic Technologies
- Genetype for Breast Cancer commissioned-Sales start Q1 2020
- Response to Appendix 3Y Query
- Non-Renounceable Rights Issue
- Director Resignation
- Collaboration Agreement signed between GTG and TGen
Later from Genetic Technologies
- Updated Form F-1 Prospectus SEC Filing
- Breast Cancer Test US Sales Update
- Half Yearly Report and Accounts
- Receipt of Delisting Notification Letter from Nasdaq
- USA Form F3 Registration Statement Lodged with SEC
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies